~~<i id='BF4BD4CA11'><strike id='BF4BD4CA11'><tt id='BF4BD4CA11'><pre id='BF4BD4CA11'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：knowledge 2025-10-01 22:59:39 - browse：37969

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： What we’ve learned from the Aduhelm mess

focus

hotspot

entertainment

focus

Aregistereddentalhygienistcleansapatient'steethatacommunityhealthcenter.JohnMoore/GettyImagesWhilest

WSS

The Readout: Gilead, Bernie Sanders, and other pharma news

KalVista pill reduced swelling 'attacks' caused by genetic disease

For Medicare Advantage, Democrats want stronger protections around AI

Vaccine advisory panel ACIP left half staffed by HHS

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

To avoid data mishandling cases, universities eye AI and other tools

focus

knowledge

focus

ChatGPT in medicine: STAT answers readers' burning questions

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

In Memoriam: Notable people who died in 2023

CDC overhauls leadership of center that led response to Covid

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biogen Alzheimer’s drug launch off to slow start

After affirmative action ruling, medical educators look to 'holistic review'

What we’ve learned from the Aduhelm mess

After affirmative action ruling, medical educators look to 'holistic review'

The history of OxyContin, told through Purdue Pharma documents

focus

Timeline: Special counsel's investigation into Trump's handling of classified documents

Biden report: The neurospychology of memory and aging

Vaccine advisory panel ACIP left half staffed by HHS

Doctors' information doesn't help them choose wisely when sick

Kim Kardashian sparks debate on benefits of full

Readout LOUD podcast: How biotech is using artificial intelligence

hotspot

hotspot

entertainment

focus